stoxline Quote Chart Rank Option Currency Glossary
  
NeoGenomics, Inc. (NEO)
13.11  0.01 (0.08%)    06-18 11:01
Open: 13.05
High: 13.18
Volume: 97,627
  
Pre. Close: 13.1
Low: 13
Market Cap: 1,674(M)
Technical analysis
2024-06-18 10:51:20 AM
Short term     
Mid term     
Targets 6-month :  17.33 1-year :  18.82
Resists First :  14.84 Second :  16.12
Pivot price 13.41
Supports First :  12.77 Second :  10.62
MAs MA(5) :  13.36 MA(20) :  13.63
MA(100) :  14.72 MA(250) :  15.29
MACD MACD :  -0.4 Signal :  -0.4
%K %D K(14,3) :  19.9 D(3) :  29.2
RSI RSI(14): 39.7
52-week High :  21.21 Low :  11.02
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NEO ] has closed above bottom band by 21.8%. Bollinger Bands are 38.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 13.26 - 13.37 13.37 - 13.45
Low: 12.77 - 12.89 12.89 - 12.97
Close: 12.94 - 13.13 13.13 - 13.25
Company Description

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

Headline News

Sat, 15 Jun 2024
NeoGenomics (NASDAQ:NEO) Trading Down 4.6% - Defense World

Thu, 13 Jun 2024
NeoGenomics (NASDAQ:NEO) Trading Down 4.6% - MarketBeat

Thu, 13 Jun 2024
Fort Myers' Mayor to Proclaim June as NeoGenomics' Commitment to Cancer Month - Business Wire

Wed, 12 Jun 2024
NeoGenomics (NASDAQ:NEO) Stock Price Up 8.8% - MarketBeat

Sat, 08 Jun 2024
NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Thu, 02 May 2024
NeoGenomics, Inc. (NASDAQ:NEO) Q1 2024 Earnings Call Transcript - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Medical - Diagnostics & Research
Shares Out 128 (M)
Shares Float 126 (M)
Held by Insiders 1.2 (%)
Held by Institutions 102.6 (%)
Shares Short 6,990 (K)
Shares Short P.Month 7,640 (K)
Stock Financials
EPS -0.67
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.25
Profit Margin -13.8 %
Operating Margin -18.1 %
Return on Assets (ttm) -3.5 %
Return on Equity (ttm) -8.9 %
Qtrly Rev. Growth 13.8 %
Gross Profit (p.s.) 0
Sales Per Share 4.78
EBITDA (p.s.) -0.17
Qtrly Earnings Growth 0 %
Operating Cash Flow -15 (M)
Levered Free Cash Flow -13 (M)
Stock Valuations
PE Ratio -19.76
PEG Ratio 4.3
Price to Book value 1.79
Price to Sales 2.72
Price to Cash Flow -109.71
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android